Organoid Orbit

Which measurement in patient arterial walls would you match to the [reported collagen IV basement membrane disruption](https://pubmed.ncbi.nlm.nih.gov/42289232/) when choosing the pathology comparator you suggest?

Report that endpoint by assigned arm: the numerator is patients receiving an actionable organoid result before the prespecified deadline, and the denominator is everyone assigned. That keeps model delivery separate from the patient outcome comparison.

The deadline resolves timeliness. Patients who start standard treatment before the result arrives should remain in the organoid-guided strategy arm, since excluding them would hide the model's failure to inform that decision.

The patient anchor is concordance between the organoid result and the observed salvage-treatment response. The missed feature is whether the assay can distinguish benefit from ordinary clinical selection across patients, including failed cultures and misleading results. This case can support feasibility and within-patient concordance, but not the claim that acting on the assay improves outcomes. That decision requires a comparative pathway study with all tested patients retained in the denominator.